What it does, plainly. Inside your cells, mitochondria pass electrons down a chain to make ATP, your body's energy currency. Methylene blue is one of the few things you can swallow that joins that chain directly, lifting complex IV activity about 30% and oxygen use by more than a third 1. It also mops up the stray electrons that would otherwise become damaging free radicals, and keeps doing it without being used up 2.
The human read. Twenty-six healthy adults on a single dose recalled 7% more and lit up more of their attention circuitry on a scanner an hour later 3. In bipolar patients already on mood stabilisers, it eased residual depression and anxiety 4, 5. The big Alzheimer's bet went the other way: a related derivative failed its phase 3 trial across thousands of patients 6.
Screen yourself before you dose. Both screens are hard gates.
Expect bright blue-green urine and a blue tongue for an hour or two. Both are harmless. Surfaces and clothing stain semi-permanently, so mind where the bottle goes.
What you actually feel. An hour after a low dose, an attention task you would have drifted through goes a little cleaner. No jitter, no crash, no racing heart — it reads less like coffee and more like your brain on a good night's sleep. The scanner data back the felt version: real activation in the regions that run sustained attention and recall, for a few hours 3.
- Same day: the bump is acute. Skip a dose and it isn't there.
- Over a month: the average day looks a touch sharper, but not dramatically.
- Years out: cell and animal work hints it slows mitochondrial decline 1, but no human trial has run long enough to prove that.
The fine print — when to skip it, and what people get wrong
More is not better. The dose-response is biphasic: it helps mitochondria at 1 to 4 mg/kg and shuts them down above 10 mg/kg 7, so scaling up because you "felt nothing" lands you worse than baseline.
Also skip during pregnancy (fetal harm reported) or breastfeeding. Severe kidney impairment means clearing it with a clinician first. The antidepressant and G6PD gates above are absolute, not "ask your doctor about it."
- 1Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, Ames BN (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. The FASEB Journal. link
- 2Rojas JC, Bruchey AK, Gonzalez-Lima F (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Progress in Neurobiology. link
- 3Rodriguez P, Zhou W, Barrett DW, Altmeyer W, Gutierrez JE, Li J, Lancaster JL, Gonzalez-Lima F, Duong TQ (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology. link
- 4Naylor GJ, Martin B, Hopwood SE, Watson Y (1987). A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biological Psychiatry. link
- 5Alda M, McKinnon M, Blagdon R, Garnham J, MacLellan S, O'Donovan C, Hajek T, Nair C, Dursun S, MacQueen G (2017). Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. British Journal of Psychiatry. link
- 6Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. The Lancet. link
- 7Bruchey AK, Gonzalez-Lima F (2008). Behavioral, Physiological and Biochemical Hormetic Responses to the Autoxidizable Dye Methylene Blue. American Journal of Pharmacology and Toxicology. link
Methylene Blue
USP pharmaceutical-grade 1% solution from compounding pharmacies costs $30–80 for a 30 ml bottle that lasts months at 5–20 mg/day. Annual cost well under $200.
A few drops in water once a day. Setup is minimal once a USP-grade source is identified. Blue staining is a nuisance but not effortful.
Rodriguez 2016 RCT (n=26 healthy adults, double-blind, fMRI) showed significant bilateral insular activation during sustained attention and a 7% improvement in short-term memory retrieval at 280 mg single oral dose. Effect is real but modest and single-trial.
Plausible mitochondrial mechanism for daily energy via cytochrome oxidase upregulation (37–70% increase in cellular O2 consumption in Atamna 2008), but no controlled trial in healthy adults has measured fatigue endpoints. Community reports are consistent but informal.
Two independent bipolar RCTs (Naylor 1987; Alda 2017) show significant reduction of residual depression and anxiety at 195–300 mg/day adjunctive to lithium or lamotrigine. Evidence is confined to bipolar populations on existing mood stabilisers — generalisation to healthy users is speculative.
Well-characterised mechanism (alternative electron transfer, hormetic dose-response) and multiple small RCTs in cognition (Rodriguez 2016) and bipolar mood (Alda 2017; Naylor 1987). No large replicated trials; the flagship Alzheimer's phase 3 (LMTM) failed (Gauthier 2016). Real signal, thin trial base.
Mechanism upregulates mitochondrial complex IV activity (Atamna 2008), but no human RCT has shown a felt wellness shift in healthy adults at chronic low dose. Subjective community reports of afternoon clarity are real but small.
Cellular and animal data show delay of senescence, complex IV preservation, and reduced oxidative load (Atamna 2008; Rojas 2012), but no human trial has demonstrated reduced mortality or extended healthspan. The flagship Alzheimer's trial (LMTM) failed phase 3 (Gauthier 2016).